Jeroen Van Renterghem1, Chris Vervaet2, Thomas De Beer3. 1. Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium. jeroen.vanrenterghem@ugent.be. 2. Laboratory of Pharmaceutical Technology, Ottergemsesteenweg 460, 9000, Ghent, Belgium. 3. Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.
Abstract
PURPOSE: The aim of this study was to investigate (i) the influence of drug solid-state (crystalline or dissolved in the polymer matrix) on the melt viscosity and (ii) the influence of the drug concentration, temperature and shear rate on polymer crystallization using rheological tests. METHODS: Poly (ethylene oxide) (PEO) (100.000 g/mol) and physical mixtures (PM) containing 10-20-30-40% (w/w) ketoprofen or 10% (w/w) theophylline in PEO were rheologically characterized. Rheological tests were performed (frequency and temperature sweeps in oscillatory shear as well as shear-induced crystallization experiments) to obtain a thorough understanding of the flow behaviour and crystallization of PEO-drug dispersions. RESULTS: Theophylline did not dissolve in PEO as the complex viscosity (η*) of the drug-polymer mixture increased as compared to that of neat PEO. In contrast, ketoprofen dissolved in PEO and acted as a plasticizer, decreasing η*. Acting as a nucleating agent, theophylline induced the crystallization of PEO upon cooling from the melt. On the other hand, ketoprofen inhibited crystallization upon cooling. Moreover, higher concentrations of ketoprofen in the drug-polymer mixture increasingly inhibited polymer crystallization. However, shear-induced crystallization was observed for all tested mixtures containing ketoprofen. CONCLUSION: The obtained rheological results are relevant for understanding and predicting HME processability (e.g., barrel temperature selection) and downstream processing such as injection moulding (e.g., mold temperature selection).
PURPOSE: The aim of this study was to investigate (i) the influence of drug solid-state (crystalline or dissolved in the polymer matrix) on the melt viscosity and (ii) the influence of the drug concentration, temperature and shear rate on polymer crystallization using rheological tests. METHODS:Poly (ethylene oxide) (PEO) (100.000 g/mol) and physical mixtures (PM) containing 10-20-30-40% (w/w) ketoprofen or 10% (w/w) theophylline in PEO were rheologically characterized. Rheological tests were performed (frequency and temperature sweeps in oscillatory shear as well as shear-induced crystallization experiments) to obtain a thorough understanding of the flow behaviour and crystallization of PEO-drug dispersions. RESULTS:Theophylline did not dissolve in PEO as the complex viscosity (η*) of the drug-polymer mixture increased as compared to that of neat PEO. In contrast, ketoprofen dissolved in PEO and acted as a plasticizer, decreasing η*. Acting as a nucleating agent, theophylline induced the crystallization of PEO upon cooling from the melt. On the other hand, ketoprofen inhibited crystallization upon cooling. Moreover, higher concentrations of ketoprofen in the drug-polymer mixture increasingly inhibited polymer crystallization. However, shear-induced crystallization was observed for all tested mixtures containing ketoprofen. CONCLUSION: The obtained rheological results are relevant for understanding and predicting HME processability (e.g., barrel temperature selection) and downstream processing such as injection moulding (e.g., mold temperature selection).
Authors: Michael M Crowley; Feng Zhang; Michael A Repka; Sridhar Thumma; Sampada B Upadhye; Sunil Kumar Battu; James W McGinity; Charles Martin Journal: Drug Dev Ind Pharm Date: 2007-09 Impact factor: 3.225
Authors: Jeroen Van Renterghem; Ashish Kumar; Chris Vervaet; Jean Paul Remon; Ingmar Nopens; Yvan Vander Heyden; Thomas De Beer Journal: Int J Pharm Date: 2016-12-01 Impact factor: 5.875
Authors: Herman Suwardie; Peng Wang; David B Todd; Viral Panchal; Min Yang; Costas G Gogos Journal: Eur J Pharm Biopharm Date: 2011-03-23 Impact factor: 5.571
Authors: Matthias E Lauer; Reto Maurer; Anne T De Paepe; Cordula Stillhart; Laurence Jacob; Rajesh James; Yuki Kojima; Rene Rietmann; Tom Kissling; Joost A van den Ende; Sabine Schwarz; Olaf Grassmann; Susanne Page Journal: Pharmaceutics Date: 2018-05-19 Impact factor: 6.321